These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J; J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953 [TBL] [Abstract][Full Text] [Related]
25. Aldosterone blockade in post-acute myocardial infarction heart failure. Pitt B; Ferrari R; Gheorghiade M; van Veldhuisen DJ; Krum H; McMurray J; Lopez-Sendon J Clin Cardiol; 2006 Oct; 29(10):434-8. PubMed ID: 17063946 [TBL] [Abstract][Full Text] [Related]
26. [Aldosterone receptor blockade after acute myocardial infarction with heart failure]. Bauersachs J; Ertl G Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569 [TBL] [Abstract][Full Text] [Related]
27. Aldosterone blockade in patients with systolic left ventricular dysfunction. Pitt B Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343 [No Abstract] [Full Text] [Related]
28. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. O'Keefe JH; Abuissa H; Pitt B Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427 [TBL] [Abstract][Full Text] [Related]
29. Aldosterone blockade and heart failure. Jessup M N Engl J Med; 2003 Apr; 348(14):1380-2. PubMed ID: 12668698 [No Abstract] [Full Text] [Related]
30. Adherence to aldosterone-blocking agents in patients with heart failure. Margolis J; Gerber RA; Roberts C; Gheorghiade M Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344 [TBL] [Abstract][Full Text] [Related]
31. Role of the selective aldosterone receptor blockers in arterial hypertension. Sierra C; Ruilope LM J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):23-5. PubMed ID: 15136969 [TBL] [Abstract][Full Text] [Related]
33. Eplerenone reduces morbidity and mortality after acute MI. Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244 [No Abstract] [Full Text] [Related]
34. The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. LePen C; Lilliu H; Keller T; Fiessinger S Pharmacoeconomics; 1998 Jul; 14(1):49-58. PubMed ID: 10182194 [TBL] [Abstract][Full Text] [Related]
35. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? Pitt B J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163 [TBL] [Abstract][Full Text] [Related]
36. Sudden death in patients with myocardial infarction. Pitt B; N Engl J Med; 2005 Sep; 353(12):1294-7; author reply 1294-7. PubMed ID: 16177257 [No Abstract] [Full Text] [Related]
37. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607 [TBL] [Abstract][Full Text] [Related]
38. Ethics and eplerenone. Gupta S; Fugh-Berman AJ; Scialli A J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747 [TBL] [Abstract][Full Text] [Related]
39. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Barnes BJ; Howard PA Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870 [TBL] [Abstract][Full Text] [Related]